Wasting syndrome: oral oxandrolone re-released in U.S

AIDS Treat News. 1995 Dec 22;(no 237):3-4.

Abstract

AIDS: More than thirty years ago, the Food and Drug Administration (FDA) approved the oral anabolic steroid oxandrolone (brand name Oxandrin) for regaining weight lost from infectious diseases. Companies in the United States have not manufactured it because of the many regulatory requirements for anabolic steroids. Oxandrolone is currently distributed in the United States by Quantum Express. Bio-Technology General Corporation has begun researching the drug for AIDS wasting, alcoholic hepatitis, Turner's syndrome in girls, and constitutional delay of growth in boys. A double-blind study of patients with AIDS-related wasting showed weight gain with the use of oxandrolone. Oxandrolone is inexpensive compared to other anabolic steroids. Oxandrolone is a Schedule III controlled substance.

Publication types

  • Newspaper Article

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications*
  • Administration, Oral
  • Cachexia / complications
  • Cachexia / drug therapy*
  • Drug Approval
  • Drug Costs
  • Humans
  • Oxandrolone / administration & dosage
  • Oxandrolone / therapeutic use*
  • United States
  • United States Food and Drug Administration

Substances

  • Oxandrolone